suggest that formation of the major vicriviroc metabolites in human liver microsomes is primarily mediated via CYP3A4. CYP2C9 and CYP3A5 most likely play a minor role in the biotransformation of this compound. These enzymology data will provide guidance to design clinical studies to address any potential drug-drug interactions.
INTRODUCTION
6 of 95% 10 mM ammonium acetate with 5% acetonitrile, adjusted to pH 6.0 with acetic acid (A) and 95% acetonitrile with 5% water (B). A linear gradient was programmed as defined in the A constant flow rate (1 ml/min) was maintained and the eluted drug-derived material was detected at 254 nm.
All LC-MS and LC-MS/MS experiments were performed by using a TSQ Quantum mass spectrometer (Thermo Electron Corp., San Jose, CA). The column effluent was split such that most (~80%) of the effluent was directed into the FSA and the remainder diverted to the mass spectrometer. This simultaneous detection of all drug-derived material by a MS and an FSA provided confirmation of the molecular weight and structure of all radioactive peaks in a simple experiment.
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LC-MS and LC-MS/MS Analysis
The mass spectrometer was nominally operated under the conditions listed in the following In LC-MS/MS experiments, ions were activated in Q2 with 25 -30 eV collision energy while maintaining the collision gas (argon) pressure at 1.2 mtorr. Following LC-MS/FSA analysis, the area of each detected radioactive peak in the FSA was expressed as a percent of the total chromatographic radioactivity (%TCR). Percentage values for characterized metabolites, when provided are therefore estimates and not derived from a validated quantitative procedure.
Enzyme Assays
Incubation with Pooled Human Liver Microsomes. To establish the optimal condition for initial velocity measurement, the linearity of vicriviroc metabolite formation was determined with respect to time (15-120 min) and microsomal P450 concentration (0.25-2 nmol/ml). Substrate concentrations of 0.1-50 µM were used to determine kinetic This article has not been copyedited and formatted. The final version may differ from this version.
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parameters. All incubations (final volume 500 µl) contained microsomes, 3 mM magnesium chloride, 1 mM β -NADP, 5 mM glucose 6-phosphate, 1.5 Units/ml glucose 6-phosphate dehydrogenase and 14 C-vicriviroc in 0.5 ml of 50 mM potassium phosphate buffer, pH 7.4 (Ghosal et al, 2005) . The incubation mixtures were pre-warmed for 2-3 min at 37°C, reactions were initiated by the addition of substrate and then terminated with ice-cold methanol. After centrifugation (~10,000g) at 4°C for 10 min, each incubation supernatant was directly analyzed by HPLC. Incubations without NADPH and boiled human liver microsomes served as negative controls. Following LC analysis, metabolite concentrations were calculated based on the peak areas following FSA detection and a five point standard curve produced by linear regression. For LC-MS analysis, supernatants were concentrated under nitrogen at room temperature. In vitro screening of 17 human P450   SUPERSOMES™ (CYP1A1, CYP1A2, CYP2A6, CYP1B1, CYP2B6, CYP2C8,   CYP2C9, CYP2C18, CYP2C19, CYP2D6, CYP2E1, CYP3A4, CYP3A5, CYP4A11, CYP4F2, CYP4F3A and CYP4F3B) were performed using a constant amount of cytochrome P450 (0.2 nmol/ml) and 14 C-vicriviroc (1 and 10 µM) for 120 min. All incubations with SUPERSOMES  were carried out as described earlier (Ghosal et al, 2005) . Insect microsomes without cDNA of human P450 were used as control. For CYP2C9 and CYP2A6, incubations were performed in TRIS-buffer (supplier's recommendation). These samples were also analyzed by LC-MS. Incubations of various concentrations of vicriviroc (1-100 µM) with CYP3A4, CYP2C9 and CYP3A5
Screening of 17 Human P450 SUPERSOMES™
were performed to calculate kinetic parameters. 
Inhibition with Chemical Inhibitors and CYP3A4-Inhibitory Monoclonal Antibody
Inhibition of vicriviroc metabolism was evaluated using both chemical inhibitors (ketoconazole, quinidine and sulfaphenazole) and inhibitory antibodies specific for CYP3A4. Human liver microsomes (0.5 nmol/ml) were preincubated with various concentrations of inhibitors/antibodies for 15 min at room temperature followed by the addition of buffer, cofactor and substrate (10 µM 14 C-Vicriviroc). The final concentration of the organic solvents in the incubation system was <1%. Incubations were performed and samples were analyzed by HPLC coupled with radioactivity detector.
Correlation Study
The HepatoScreen™ Test Kit consisted of 10 individual human liver microsomal preparations from 10 individual donors. The ability of human liver microsomes from each donor to metabolize vicriviroc to its metabolites were correlated with the P450-specific enzyme activities for each sample from each kit. The assays were performed as described previously (under human liver microsomal incubations) with 10 µM substrate and incubated for 120 min.
Analysis of Kinetic Data. Untransformed enzyme kinetic data were analyzed by a nonlinear regression data analysis program (GraFit 5.0.1, Erithacus Software Limited, Staines, UK), assuming Michaelis-Menten kinetics over the substrate range studied.
Results

Optimization and Incubation with Pooled Human Liver Microsomes.
Incubation of 14 C-vicriviroc (Figure 1 ) with human liver microsomes yielded a variety of metabolites which could be separated by HPLC. When pooled human liver microsomes were incubated with 10 µM 14 C-vicriviroc over a range of concentrations of cytochrome P450 (0.25-2 nmol/ml) for various time periods (15-120 min), a P450 concentration of 0.5 nmol/ml and incubation time of 120 min were found to be optimal (not shown).
Radiochromatographic profiles of metabolites following incubation of vicriviroc (1 and 10 µM) with human liver microsomes are presented in Figure 2 . No metabolite formation was observed in the absence of the NADPH-generating system (not shown) or with boiled microsomes (Figure 2) . Kinetic parameters for the production of various metabolites are shown in obtained from BD-Bioscience (Woburn, MA) and human liver microsomes were determined in assays using fluorometric substrates as described previously (Ghosal et al, 2003) . The results of the activity determination of 13 human P450 SUPERSOMES  and human liver microsomes demonstrated that the SUPERSOMES  and microsomes were active (not shown). The activity of CYP4A11, CYP4F2, CYP4F3A, and CYP4F3B
were not determined.
Metabolite Identification
This article has not been copyedited and formatted. The final version may differ from this version. suggests that an alteration is most likely occurring on the 4,6-dimethyl-5-pyrimidinylcarbonyl moiety of vicriviroc. Modification in this region was further confirmed by a 4 Da shift of the fragment ion at m/z 232 to 236 Th. Using previously described APCI-MS and hydrogen/deuterium exchange mass spectrometry (Ramanathan et al, 2005b ) and accurate mass measurement, M7 was characterized as vicriviroc-hydoxylamine.
Unambiguous identification of M7 involved matching HPLC retention time and the MS/MS spectrum with that of the synthetic reference standard (SCH 727390). To our knowledge, the biotransformation of pyrimidine moiety to a pyrazyl-hydroxylamine has not been previously reported. The mechanism of this intriguing metabolic process is currently being investigated.
Other minor CYP3A4 mediated metabolites M16, M35b/M37a and M45-M47 The biotransformation pathway of vicriviroc is presented in Figure 7 .
Correlation Analysis
The formation rate of 14 C-vicriviroc metabolites (M2/M3, M15, and M41) were measured in each of the 10 human liver microsomal samples provided in the HepatoScreen ® Test Kit. These values were then correlated with the biochemical activity data provided by the manufacturer. Since the biochemical activity data were mediated by specific CYP enzymes, high correlation would suggest that similar enzymes were involved in the formation of metabolites from vicriviroc.
The highest correlation between the HepatoScreen ® Test Kit assay data (n=10) and the formation of M2/M3, M15, M41 was noted for dextromethorphan Ndemethylation (r≥0.89) which is catalyzed by CYP3A4 (Table 4) . Correlations among M2/M3 (r=0.91, p=0.0003), M15 (r=0.93, p=0.0001), M41 (r=0.97, p<0.0001) and testosterone 6β-hydroxylation catalyzed by CYP3A4/5 were also significant ( Table 4) .
A representative correlation plot of M41 is provided in Figure 8 . the findings are consistent with a significant correlation between the activity of CYP2B6 SUPERSOMES  and CYP3A4 observed by other investigators (Heyn et al, 1996) .
There was no significant correlation between tolbutamide methyl-hydroxylation (CYP2C9) and M15 formation. Overall, correlation analysis between the enzyme activities and metabolite formation suggested that vicriviroc is metabolized primarily by CYP3A4 in human liver microsomes.
Inhibition Studies
All inhibition studies were performed with pooled human liver microsomes at a drug concentration of 10 µM. Ketoconazole was shown to be a potent inhibitor of vicriviroc metabolism (all metabolites) by human liver microsomes ( Table 5 ). The mean IC50 value of ketoconazole for M2/M3, M15 and M41 formation from human liver microsomes were 0.84, 1.1 and 0.79 µM, respectively (Table 5) . Azamulin, a specific CYP3A4/5-inhibitor, inhibited M2/M3, M15 and M41 formation from human liver microsomes by 90-100% (Table 5 ) at 5 µM concentration. Neither quinidine (CYP2D6 inhibitor) at 5 µM nor sulfaphenazole (CYP2C9-specific inhibitor) at 0.5 and 3 µM had a significant effect on the metabolism of vicriviroc (Table 5) .
Studies with CYP3A4/5-specific inhibitory monoclonal antibody showed significant inhibitory effect on the metabolism of vicriviroc (Figure 9 ). CYP3A4/5-specific inhibitory monoclonal antibody (1 µg/µg protein) inhibited the formation of M41, M2/M3, M15, M35b/M37a from human liver microsomes by 86, 83, 78 and 100%, respectively, whereas control experiments showed no inhibition.
In vitro incubation with 17 different recombinant human P450 SUPERSOMES
 showed that CYP3A4 exhibited the most activity followed by CYP2C9 and CYP3A5.
The formation of metabolites with recombinant CYP2C9, CYP3A4, and CYP3A5
suggested minimal involvement of CYP2C9 and CYP3A5 in the metabolism of vicriviroc.
In human liver microsomes, the apparent Km (8.92 µM) for M41 is lower than the Km values in CYP3A4 and CYP3A5 (25.6 and 51 µM). In the present study, formation of Hutzler et al, (2001) suggested that the activation of CYP2C9-mediated dapsone metabolism and its biphasic profile may be explained by a two-site binding mode.
Interestingly, incubations of vicriviroc with human liver microsomes do not show
This article has not been copyedited and formatted. The final version may differ from this version. biphasic behavior for the formation of M15, as M15 is largely mediated by CYP3A4 and it also plays a minor role in the metabolism of vicriviroc.
Ketoconazole (Desai et al, 1998; Newton et al, 1995; Ghosal et al, 1996; Masimirembwa et al, 1999; Wrighton et al, 1994) and azamulin (Stresser et al, 2004) (both CYP3A4-selective inhibitor), were shown to be potent inhibitors of vicriviroc metabolism by human liver microsomes suggesting the involvement of CYP3A4 in its metabolism. Stresser et al (2004) reported that azamulin is a highly potent and selective inhibitor of CYP3A. However, sulfaphenazole (CYP2C9-selective inhibitor, Newton et al, 1995) had no significant effect on the metabolism of vicriviroc, suggesting that CYP2C9 plays a minor role in the metabolism of vicriviroc. Studies with CYP3A4/5 inhibitory antibody demonstrated that it inhibited >80% of vicriviroc metabolism in human liver microsomes. In addition, there was a significant correlation between the formation of M2/M3, M15, M41 and dextromethorphan N-demethylation or testosterone 6β-hydroxylation, known to be mediated by CYP3A4 (Newton et al, 1995; Gorski et al, 1994 ). These inhibition and correlation studies suggest that CYP3A4 is primarily responsible for the biotransformation of vicriviroc.
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